ArticlePloS one2017

Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Yvonne W S Jauw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.